RPRX

32.29

1.61% -0.53

Dopo l'orario di chiusura: 32.23 -0.06 -0.19%

Royalty Pharma Plc (RPRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Precedente Chiudi:

$32.82

Aprire:

$32.87

Volume 24 ore:

3.58M

Relative Volume:

0.79

Capitalizzazione di mercato:

$13.80B

Reddito:

$2.26B

Utile/perdita netta:

$1.09B

Rapporto P/E:

13.78

EPS:

2.3431

Flusso di cassa netto:

$2.70B

1 W Prestazione:

-1.40%

1M Prestazione:

+0.00%

6M Prestazione:

+26.23%

1 anno Prestazione:

+15.03%

Intervallo 1D:

$32.18

$33.11

Intervallo di 1 settimana:

$32.18

$34.11

Portata 52W:

$24.05

$34.20

Royalty Pharma Plc Stock (RPRX) Company Profile

Nome

Royalty Pharma Plc

Settore

Healthcare (1149)

Industria

Biotechnology (673)

Telefono

(212) 883-0200

Indirizzo

110 EAST 59TH STREET, NEW YORK, NY

Dipendente

Cinguettio

Prossima data di guadagno

2025-02-11

Ultimi documenti SEC

RPRX's Discussions on Twitter

Confronta RPRX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RPRX Royalty Pharma Plc	32.29	13.80B	2.26B	1.09B	2.70B	2.3431
VRTX Vertex Pharmaceuticals Inc	421.16	111.66B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	571.36	60.56B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	532.27	38.04B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	267.55	36.06B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	219.95	25.10B	3.81B	-644.79M	-669.77M	-6.24

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-06-03	Downgrade	UBS	Buy → Neutral
2022-06-14	Ripresa	UBS	Buy
2022-05-13	Iniziato	Scotiabank	Sector Outperform
2022-04-27	Iniziato	Goldman	Buy
2022-04-14	Aggiornamento	JP Morgan	Neutral → Overweight
2022-04-06	Ripresa	Morgan Stanley	Overweight
2021-10-29	Aggiornamento	Citigroup	Neutral → Buy
2021-07-30	Iniziato	Tigress Financial	Buy
2020-11-09	Aggiornamento	UBS	Neutral → Buy
2020-07-14	Iniziato	Evercore ISI	In-line
2020-07-13	Iniziato	BofA Securities	Buy
2020-07-13	Iniziato	Citigroup	Neutral
2020-07-13	Iniziato	Cowen	Outperform
2020-07-13	Iniziato	Goldman	Neutral
2020-07-13	Iniziato	JP Morgan	Neutral
2020-07-13	Iniziato	Morgan Stanley	Equal-Weight
2020-07-13	Iniziato	SunTrust	Buy
2020-07-13	Iniziato	UBS	Neutral

Mostra tutto

Royalty Pharma Plc Borsa (RPRX) Ultime notizie

07:14 AM

Royalty Pharma at Bank of America 2025 Healthcare: Strategic Growth Insights - Investing.com UK

07:14 AM

11:52 AM

Learn to Evaluate (RPRX) using the Charts - news.stocktradersdaily.com

11:52 AM

05:02 AM

Royalty Pharma plc (NASDAQ:RPRX) Position Raised by Deutsche Bank AG - MarketBeat

05:02 AM

04:24 AM

Axa S.A. Acquires 138,017 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

04:24 AM

01:32 AM

Crestline Management LP Acquires 79,532 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

01:32 AM

May 13, 2025

Bridgefront Capital LLC Invests $311,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 13, 2025

Royalty Pharma to Present at Upcoming Investor Conferences - The Manila Times

May 13, 2025

BNP Paribas Financial Markets Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 13, 2025

D. E. Shaw & Co. Inc. Raises Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 13, 2025

May 12, 2025

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition - citybiz

May 12, 2025

Royalty Pharma Shareholders Approve External Manager Acquisition - marketscreener.com

May 12, 2025

Royalty Pharma shareholders approve manager acquisition - Investing.com Australia

May 12, 2025

Royalty Pharma shareholders approve manager acquisition By Investing.com - Investing.com Nigeria

May 12, 2025

Royalty Pharma’s Annual General Meeting Highlights - TipRanks

May 12, 2025

Royalty Pharma Shareholders Approve Internalization of Management with 99.9% Support, Expected to Drive Over $1.6 Billion in Cost Savings - Nasdaq

May 12, 2025